Ftse Mib
33.414,56
0,46%
DAX
19.626,45
1,05%
S&P 500
6.032,38
0,56%
NASDAQ
19.218,17
0,83%
Bitcoin
97.061,06
-0,43%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Eledon Pharmaceuticals Inc (ELDN) Eledon Pharmaceuticals Inc (ELDN) Notizie

ELDN

Eledon Pharmaceuticals (ELDN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ELDN
DataOraFonteTitoloSimboloCompagnia
22/11/202423:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELDNEledon Pharmaceuticals Inc
14/11/202422:51Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ELDNEledon Pharmaceuticals Inc
12/11/202423:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ELDNEledon Pharmaceuticals Inc
12/11/202422:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELDNEledon Pharmaceuticals Inc
12/11/202422:01GlobeNewswire Inc.Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial ResultsNASDAQ:ELDNEledon Pharmaceuticals Inc
06/11/202422:05GlobeNewswire Inc.Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation ConferenceNASDAQ:ELDNEledon Pharmaceuticals Inc
05/11/202417:44Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ELDNEledon Pharmaceuticals Inc
30/10/202411:36Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ELDNEledon Pharmaceuticals Inc
29/10/202412:46GlobeNewswire Inc.Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsNASDAQ:ELDNEledon Pharmaceuticals Inc
29/10/202412:45GlobeNewswire Inc.Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago MedicineNASDAQ:ELDNEledon Pharmaceuticals Inc
03/10/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ELDNEledon Pharmaceuticals Inc
20/09/202422:16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ELDNEledon Pharmaceuticals Inc
11/09/202422:05GlobeNewswire Inc.Eledon Pharmaceuticals to Present at the Cantor Global Healthcare ConferenceNASDAQ:ELDNEledon Pharmaceuticals Inc
04/09/202413:00GlobeNewswire Inc.Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant PatientsNASDAQ:ELDNEledon Pharmaceuticals Inc
19/08/202422:33Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:ELDNEledon Pharmaceuticals Inc
19/08/202422:30Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:ELDNEledon Pharmaceuticals Inc
14/08/202423:21GlobeNewswire Inc.Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating ResultsNASDAQ:ELDNEledon Pharmaceuticals Inc
14/08/202423:12Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:ELDNEledon Pharmaceuticals Inc
29/07/202413:00GlobeNewswire Inc.Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ RejectionNASDAQ:ELDNEledon Pharmaceuticals Inc
02/07/202422:05GlobeNewswire Inc.Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and MetabolismNASDAQ:ELDNEledon Pharmaceuticals Inc
06/06/202422:01Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ELDNEledon Pharmaceuticals Inc
03/06/202422:01GlobeNewswire Inc.Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney TransplantationNASDAQ:ELDNEledon Pharmaceuticals Inc
30/05/202422:25Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ELDNEledon Pharmaceuticals Inc
30/05/202422:05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ELDNEledon Pharmaceuticals Inc
09/05/202413:30GlobeNewswire Inc.Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial ResultsNASDAQ:ELDNEledon Pharmaceuticals Inc
09/05/202413:00GlobeNewswire Inc.Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant CongressNASDAQ:ELDNEledon Pharmaceuticals Inc
07/05/202413:05GlobeNewswire Inc.Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant RejectionNASDAQ:ELDNEledon Pharmaceuticals Inc
07/05/202413:00GlobeNewswire Inc.Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private PlacementNASDAQ:ELDNEledon Pharmaceuticals Inc
28/03/202421:01GlobeNewswire Inc.Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial ResultsNASDAQ:ELDNEledon Pharmaceuticals Inc
25/03/202421:56GlobeNewswire Inc.Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ RejectionNASDAQ:ELDNEledon Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ELDN

La tua Cronologia

BOV
AESO3T
AES Brasil Operacoes
BOV
ALZR11
Alianza Trust Renda Imob...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network